Physiological changes in metabolic disorders of bone and evaluation of agents used in their treatment.
D000728:Androgens / Q000627:therapeutic use; D001847:Bone Diseases / Q000188:drug therapy / Q000378:metabolism* / Q000503:physiopathology; D011756:Diphosphates / Q000627:therapeutic use; D004967:Estrogens / Q000627:therapeutic use; D005459:Fluorides / Q000627:therapeutic use; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D006961:Hyperparathyroidism / Q000188:drug therapy; D008659:Metabolic Diseases / Q000188:drug therapy / Q000503:physiopathology*; D063065:Organophosphonates / Q000627:therapeutic use; D010001:Osteitis Deformans / Q000188:drug therapy; D010018:Osteomalacia / Q000188:drug therapy; D010024:Osteoporosis / Q000188:drug therapy / Q000503:physiopathology; D010281:Parathyroid Hormone; D010710:Phosphates / Q000627:therapeutic use; D008926:Plicamycin / Q000627:therapeutic use
D000728:Androgens; D011756:Diphosphates; D004967:Estrogens; D063065:Organophosphonates; D010281:Parathyroid Hormone; D010710:Phosphates; D006493:Heparin; D008926:Plicamycin; D005459:Fluorides